| NCT ID | NCT04707001 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Finland Hospital District |
| Condition | Urinary Retention Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2021-05-01 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 170 participants in total. It began in 2021-05-01 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Arthroplasty increases the risk of postoperative urinary retention. Treatment of postoperative urinary retention is indwelling or intermittent catheterization. The need for catheterization is most commonly determined with an ultrasound scanner. Catheterization increases the risk of urinary tract infection, which may further lead to haematogenic infection of the artificial joint. There is no evidence of an optimal way to monitor the onset of spontaneous urination. The aim of the study is to determine whether monitoring the onset of spontaneous urination after fast track knee arthroplasty is safe based on symptoms alone without ultrasound monitoring.
Eligibility Criteria
Inclusion Criteria: * elective total knee arthroplasty Exclusion Criteria: * previous surgery for urologic cancer * fracture as indication for surgery * lack of co-operation * untreated urinary retention * nephrostoma * general anesthesia
Contact & Investigator
Juha Paloneva, professor
PRINCIPAL INVESTIGATOR
Chief medical director
Frequently Asked Questions
Who can join the NCT04707001 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary Retention Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04707001 currently recruiting?
Yes, NCT04707001 is actively recruiting participants. Contact the research team at juha.paloneva@ksshp.fi for enrollment information.
Where is the NCT04707001 trial being conducted?
This trial is being conducted at Jyväskylä, Finland.
Who is sponsoring the NCT04707001 clinical trial?
NCT04707001 is sponsored by Central Finland Hospital District. The principal investigator is Juha Paloneva, professor at Chief medical director. The trial plans to enroll 170 participants.